Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.

Pathology - 1 Dec 2021

Leitinger E J, Wright R M, Nelson N, Anderson M A, Juneja S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Lymphoma, Mantle-Cell

Share to Piperidines

Share to Sulfonamides

Source

Identifiers

PMID: 33947523
DOI: 10.1016/j.pathol.2021.01.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Nov 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.PMID 33947523Read ↗

Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markersSemantic proximity Read ↗

The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testingSemantic proximity Read ↗

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphomaSemantic proximity Read ↗

First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.Semantic proximity Read ↗

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.Semantic proximity Read ↗

Immunophenotyping of lymphoproliferative disorders: state of the art.Semantic proximity Read ↗

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.Semantic proximity Read ↗

Safety and Efficacy of Mosunetuzumab: Experience in the A.O. Card G. PanicoSemantic proximity Read ↗

Emerging diagnostic tests for vitreoretinal lymphoma: a review.Semantic proximity Read ↗

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Semantic proximity Read ↗

Atypical COVID-19 dynamics in a patient with Mantle Cell Lymphoma Exposed to RituximabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.